Matt Aaron Tschantz

USPTO Granted Patents = 11 (Patent Applications = 5)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 428(Granted Patents)

Company Filing History:

6 out of 1,535

Boehringer Ingelheim International Gmbh

patents

5 out of 276

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

Years Active: 2003-2018

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9975882 - Heteroaromatic compounds as BTK inhibitors (2018-05-22),

2. 9533999 - Fused thiazin-3-ones as KCA3.1 inhibitors (2017-01-03),

3. 8552205 - Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides (2013-10-08),

4. 8481750 - [object Object] (2013-07-09),

5. 7601714 - Pyrimidine derivatives useful as inhibitors of PKC-theta (2009-10-13),

6. 7572921 - Substituted benzylimidazoles useful for the treatment of inflammatory diseases (2009-08-11),

7. 7468382 - Pyridine derivatives useful as inhibitors of PKC-theta (2008-12-23),

8. 7462637 - [object Object] (2008-12-09),

9. 6852748 - Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide (2005-02-08),

10. 6770639 - Heterocyclic compounds useful as inhibitors of tyrosine kinases (2004-08-03),

11. 6506769 - Heterocyclic compounds useful as inhibitors of tyrosine kinases (2003-01-14),

Title: The Innovative Contributions of Matt Aaron Tschantz

Introduction

Matt Aaron Tschantz is a notable inventor based in Newtown, CT, with a remarkable portfolio of 11 patents. His work primarily focuses on the development of pharmaceutical compounds that target specific diseases, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest patents, Tschantz has developed heteroaromatic compounds as BTK inhibitors. This invention encompasses compounds of a specific formula that are suitable for treating diseases related to BTK. Additionally, he has created fused thiazin-3-ones as KCa3.1 inhibitors, which are also designed for the treatment of diseases related to KCa3.1. Both patents include processes for making these compounds, pharmaceutical preparations containing them, and their methods of use.

Career Highlights

Tschantz has made significant contributions while working at Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. His experience in these reputable companies has allowed him to refine his skills and innovate in the pharmaceutical field.

Collaborations

Throughout his career, Tschantz has collaborated with talented individuals such as Jin Mi Kim and Bryan Patrick McKibben. These partnerships have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Matt Aaron Tschantz's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to impact the treatment of various diseases, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.